CA2867668A1 - Compounds and methods for treating aberrant adrenocortical cell disorders - Google Patents
Compounds and methods for treating aberrant adrenocortical cell disorders Download PDFInfo
- Publication number
- CA2867668A1 CA2867668A1 CA2867668A CA2867668A CA2867668A1 CA 2867668 A1 CA2867668 A1 CA 2867668A1 CA 2867668 A CA2867668 A CA 2867668A CA 2867668 A CA2867668 A CA 2867668A CA 2867668 A1 CA2867668 A1 CA 2867668A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- phenyl
- atr
- administering
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614269P | 2012-03-22 | 2012-03-22 | |
| US61/614,269 | 2012-03-22 | ||
| PCT/US2013/031068 WO2013142214A1 (en) | 2012-03-22 | 2013-03-13 | Compounds and methods for treating aberrant adrenocartical cell disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2867668A1 true CA2867668A1 (en) | 2013-09-26 |
Family
ID=48014328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2867668A Abandoned CA2867668A1 (en) | 2012-03-22 | 2013-03-13 | Compounds and methods for treating aberrant adrenocortical cell disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9107883B2 (enExample) |
| EP (1) | EP2838523A1 (enExample) |
| JP (2) | JP6234987B2 (enExample) |
| CN (2) | CN104302283B (enExample) |
| AU (2) | AU2013235535B2 (enExample) |
| BR (1) | BR112014023517B1 (enExample) |
| CA (1) | CA2867668A1 (enExample) |
| HK (1) | HK1206607A1 (enExample) |
| IN (1) | IN2014DN08604A (enExample) |
| MX (1) | MX355129B (enExample) |
| NZ (1) | NZ630828A (enExample) |
| WO (1) | WO2013142214A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2748238B2 (ja) | 1994-12-20 | 1998-05-06 | 新興機械工業株式会社 | ばね製造装置の足起こし装置 |
| US9107883B2 (en) * | 2012-03-22 | 2015-08-18 | Atterocor, Inc. | Compounds and methods for treating aberrant adrenocartical cell disorders |
| US20150087649A1 (en) * | 2013-09-26 | 2015-03-26 | Atterocor, Inc. | Treating disorders associated with aberrant adrenocortical cell behavior |
| CN107205941A (zh) * | 2014-09-26 | 2017-09-26 | 米伦多治疗公司 | N‑(2,6‑二(1‑甲基乙基)苯基)‑n′‑((1‑(4‑(二甲基氨基)苯基)环戊基)甲基)脲盐酸盐的固体药物形式以及涉及其的组合物、方法和试剂盒 |
| WO2016164476A2 (en) * | 2015-04-06 | 2016-10-13 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| US20180200209A1 (en) * | 2015-07-10 | 2018-07-19 | Millendo Therapeutics, Inc. | Enhanced bioavailability of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl)methyl)urea hydrochloride |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| US10231983B1 (en) | 2018-08-22 | 2019-03-19 | Corcept Therapeutics, Inc. | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US11202787B2 (en) | 2018-07-02 | 2021-12-21 | Corcept Therapeutics, Inc. | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US10780097B2 (en) | 2018-07-02 | 2020-09-22 | Corcept Therapeutics, Inc. | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US20220241276A1 (en) * | 2019-06-11 | 2022-08-04 | The Regents Of The University Of Michigan | Compositions and methods for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5015644A (en) | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| NZ577219A (en) * | 2006-12-06 | 2011-11-25 | Smithkline Beecham Corp | Bicyclic compounds and use as antidiabetics |
| WO2009067397A2 (en) * | 2007-11-19 | 2009-05-28 | Ore Pharmaceuticals Inc. | Treatment for solid tumors |
| US9107883B2 (en) * | 2012-03-22 | 2015-08-18 | Atterocor, Inc. | Compounds and methods for treating aberrant adrenocartical cell disorders |
-
2013
- 2013-03-13 US US13/802,047 patent/US9107883B2/en active Active
- 2013-03-13 MX MX2014011188A patent/MX355129B/es active IP Right Grant
- 2013-03-13 CA CA2867668A patent/CA2867668A1/en not_active Abandoned
- 2013-03-13 WO PCT/US2013/031068 patent/WO2013142214A1/en not_active Ceased
- 2013-03-13 IN IN8604DEN2014 patent/IN2014DN08604A/en unknown
- 2013-03-13 BR BR112014023517-1A patent/BR112014023517B1/pt active IP Right Grant
- 2013-03-13 CN CN201380015269.0A patent/CN104302283B/zh active Active
- 2013-03-13 JP JP2015501763A patent/JP6234987B2/ja active Active
- 2013-03-13 NZ NZ630828A patent/NZ630828A/en unknown
- 2013-03-13 HK HK15107166.6A patent/HK1206607A1/xx unknown
- 2013-03-13 CN CN201610595176.5A patent/CN106236741A/zh active Pending
- 2013-03-13 EP EP13712998.7A patent/EP2838523A1/en not_active Withdrawn
- 2013-03-13 AU AU2013235535A patent/AU2013235535B2/en active Active
-
2015
- 2015-07-13 US US14/798,237 patent/US9446010B2/en active Active
-
2016
- 2016-06-01 US US15/170,682 patent/US9877937B2/en active Active
-
2017
- 2017-06-26 JP JP2017124186A patent/JP6317016B2/ja active Active
- 2017-11-17 AU AU2017261632A patent/AU2017261632A1/en not_active Abandoned
- 2017-12-12 US US15/839,647 patent/US20180256524A1/en not_active Abandoned
-
2021
- 2021-06-30 US US17/364,464 patent/US20220160662A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013235535B2 (en) | 2017-09-21 |
| US20160367507A1 (en) | 2016-12-22 |
| HK1206607A1 (en) | 2016-01-15 |
| CN106236741A (zh) | 2016-12-21 |
| US9877937B2 (en) | 2018-01-30 |
| AU2017261632A1 (en) | 2017-12-07 |
| NZ630828A (en) | 2016-10-28 |
| AU2013235535A1 (en) | 2014-10-09 |
| US20220160662A1 (en) | 2022-05-26 |
| US9107883B2 (en) | 2015-08-18 |
| CN104302283B (zh) | 2016-08-24 |
| US9446010B2 (en) | 2016-09-20 |
| JP6317016B2 (ja) | 2018-04-25 |
| IN2014DN08604A (enExample) | 2015-05-22 |
| US20160008302A1 (en) | 2016-01-14 |
| JP2017160275A (ja) | 2017-09-14 |
| US20130267550A1 (en) | 2013-10-10 |
| BR112014023517B1 (pt) | 2020-12-01 |
| CN104302283A (zh) | 2015-01-21 |
| US20180256524A1 (en) | 2018-09-13 |
| EP2838523A1 (en) | 2015-02-25 |
| MX355129B (es) | 2018-04-06 |
| MX2014011188A (es) | 2015-03-06 |
| JP2015510933A (ja) | 2015-04-13 |
| JP6234987B2 (ja) | 2017-11-22 |
| WO2013142214A1 (en) | 2013-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220160662A1 (en) | Compounds and methods for treating aberrant adrenocortical cell disorders | |
| TWI289449B (en) | Compositions and methods for the treatment of cancer | |
| US20020128228A1 (en) | Compositions and methods for the treatment of cancer | |
| USRE49647E1 (en) | Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
| US20230310354A1 (en) | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer | |
| CN102908346A (zh) | 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮在套细胞淋巴瘤治疗中的用途 | |
| AU2003290982A1 (en) | Pharmaceutical compositions and dosage forms of thalidomide | |
| US12090147B2 (en) | Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| US20200206212A1 (en) | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| TW201642857A (zh) | 以組合療法治療肝細胞癌 | |
| HK1230524A (en) | Compounds and methods for treating aberrant adrenocartical cell disorders | |
| HK1230524A1 (en) | Compounds and methods for treating aberrant adrenocartical cell disorders | |
| US20240216465A1 (en) | Method for treating refractory brain tumor | |
| US10646479B2 (en) | Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment for cancer | |
| TW202428876A (zh) | 治療難治型腦瘤之方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180122 |
|
| FZDE | Discontinued |
Effective date: 20211013 |